MINNEAPOLIS, Nov. 09, 2017 — Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, today announced it has partnered with Device Technologies, an established distributor of quality and technologically-advanced medical equipment, to market the STREAMWAY System in Australia, New Zealand, Fiji and the Pacific Islands.
Founded in 1992, Device Technologies employs more than 600 healthcare specialists and support staff in Australia and New Zealand. All the products it distributes are professionally supported by qualified Product Managers and specialists who are trained to work in surgical and operating room environments. It has on staff Clinical Educators to provide accredited training, in-servicing and ongoing clinical support, as well as Technical Service personnel to service and maintain its extensive range of capital equipment.“Device Technologies has an outstanding reputation for providing high quality medical products to hospitals in its home markets of Australia and New Zealand, where it is considered a leading distributor,” commented Dr. Carl Schwartz, chief executive officer of Skyline Medical. “We are confident that Device Technologies’ regional knowledge, local contacts and on-the-ground sales reps will support sales of the STREAMWAY System as we look to expand into these new markets. This distribution agreement is the latest milestone in our international expansion strategy, and follows the recent signing of partnerships with two independent distributors in Canada and Switzerland. We believe the STREAMWAY has the potential to generate strong sales in these markets and are excited to leverage this international opportunity.”Skyline’s distributors are all selected based on stringent requirements, including a demonstrable track record selling medical equipment, strong industry contacts and deep technical knowledge of the STREAMWAY System.About the STREAMWAY SystemSkyline's revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a facility's plumbing system to automate the collection, measurement and disposal of waste fluids. The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater profitability. Furthermore, the STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the U.S. For a demonstration please visit www.skylinemedical.com or call 855-785-8855.About Skyline MedicalSkyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with OSHA and other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S. For additional information, please visit www.skylinemedical.com.Forward-looking StatementsCertain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to the proposed joint ventures with Helomics, Corporation and CytoBioscience, Inc, including the need to negotiate the definitive agreements for the joint ventures; possible failure to realize anticipated benefits of the joint ventures; and costs of providing funding to the joint ventures. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.Contacts:Skyline Medical
Carl Schwartz, Chief Executive Officer
KCSA Strategic Communications
Latest posts by Brad Bennett (see all)
- Ephesoft Names Naren Goel as Chief Financial Officer - February 22, 2018
- HNTB names Jim Thomson new senior vice president - February 22, 2018
- ITS Logistics announces promotion of Jamie Lawson to CFO - February 22, 2018